# Matej Skorvanek

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/238011/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 66 papers | 1,632 citations | 304743 22 h-index | 345221 36 g-index |
| 66 all docs | 66 docs citations | 66 times ranked | 2465 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Monogenic variants in dystonia: an exome-wide sequencing study. Lancet Neurology, The, 2020, 19, 908-918. | 10.2 | 139 |
| 2 | Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. Movement Disorders, 2018, 33, 208-218. | 3.9 | 138 |
| 3 | The Clinical Syndrome of Paroxysmal Exercise-Induced Dystonia: Diagnostic Outcomes and an Algorithm. Movement Disorders Clinical Practice, 2014, 1, 57-61. | 1.5 | 100 |
| 4 | The associations between fatigue, apathy, and depression in Parkinson's disease. Acta Neurologica Scandinavica, 2015, 131, 80-87. | 2.1 | 93 |
| 5 | Lossâ€ofâ€Function Variants in <scp>HOPS</scp> Complex Genes <scp>VPS16</scp> and <scp>VPS41</scp> Cause Early Onset Dystonia Associated with Lysosomal Abnormalities. Annals of Neurology, 2020, 88, 867-877. | 5.3 | 70 |
| 6 | Differences in <scp>MDS</scp>â€<scp>UPDRS</scp> Scores Based on Hoehn and Yahr Stage and Disease Duration. Movement Disorders Clinical Practice, 2017, 4, 536-544. | 1.5 | 65 |
| 7 | De novo variants in neurodevelopmental disordersâ€"experiences from a tertiary care center. Clinical Genetics, 2021, 100, 14-28. | 2.0 | 64 |
| 8 | Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin. Frontiers in Neurology, 2017, 8, 35. | 2.4 | 63 |
| 9 | Relationship between the non-motor items of the MDSâ€"UPDRS and Quality of Life in patients with Parkinson's disease. Journal of the Neurological Sciences, 2015, 353, 87-91. | 0.6 | 58 |
| 10 | Paroxysmal exercise-induced dystonia within the phenotypic spectrum ofECHS1deficiency. Movement Disorders, 2016, 31, 1041-1048. | 3.9 | 58 |
| 11 | Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations. Movement Disorders, 2021, 36, 283-297. | 3.9 | 52 |
| 12 | Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. Movement Disorders, 2019, 34, 791-798. | 3.9 | 49 |
| 13 | Rating Scales for Pain in Parkinson's Disease: Critique and Recommendations. Movement Disorders Clinical Practice, 2016, 3, 527-537. | 1.5 | 46 |
| 14 | Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. Parkinsonism and Related Disorders, 2018, 52, 83-89. | 2.2 | 46 |
| 15 | Accuracy of Rating Scales and Clinical Measures for Screening of Rapid Eye Movement Sleep Behavior Disorder and for Predicting Conversion to Parkinsonâ€™s Disease and Other Synucleinopathies. Frontiers in Neurology, 2018, 9, 376. | 2.4 | 39 |
| 16 | The Skin and Parkinson's Disease: Review of Clinical, Diagnostic, and Therapeutic Issues. Movement Disorders Clinical Practice, 2017, 4, 21-31. | 1.5 | 37 |
| 17 | Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication. Frontiers in Neurology, 2019, 10, 799. | 2.4 | 34 |
| 18 | Update on the Management of Parkinsonâ€™s Disease for General Neurologists. Parkinson's Disease, 2020, 2020, 1-13. | 1.1 | 33 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Validation study of the hoehn and yahr scale included in the MDSâ€UPDRS. Movement Disorders, 2018, 33, 651-652. | 3.9 | 32 |
| 20 | Apathy in Elderly Nondemented Patients With Parkinson's Disease. Journal of Geriatric Psychiatry and Neurology, 2013, 26, 237-243. | 2.3 | 30 |
| 21 | Clinical determinants of primary and secondary fatigue in patients with Parkinsonâ€™s disease. Journal of Neurology, 2013, 260, 1554-1561. | 3.6 | 29 |
| 22 | The role of social support in anxiety and depression among Parkinsonâ€™s disease patients. Disability and Rehabilitation, 2014, 36, 2044-2049. | 1.8 | 24 |
| 23 | Prevalence of nonâ€motor symptoms and their association with quality of life in cervical dystonia. Acta Neurologica Scandinavica, 2020, 142, 613-622. | 2.1 | 22 |
| 24 | Neurodevelopmental disorder associated with IRF2BPL gene mutation: Expanding the phenotype?. Parkinsonism and Related Disorders, 2019, 62, 239-241. | 2.2 | 20 |
| 25 | Measurement of Nonmotor Symptoms in Clinical Practice. International Review of Neurobiology, 2017, 133, 291-345. | 2.0 | 18 |
| 26 | Blood DNA methylation provides an accurate biomarker of KMT2B-related dystonia and predicts onset. Brain, 2022, 145, 644-654. | 7.6 | 18 |
| 27 | Recessive variants in ZNF142 cause a complex neurodevelopmental disorder with intellectual disability, speech impairment, seizures, and dystonia. Genetics in Medicine, 2019, 21, 2532-2542. | 2.4 | 17 |
| 28 | Randomised controlled trial of escitalopram for cervical dystonia with dystonic jerks/tremor. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 579-585. | 1.9 | 15 |
| 29 | Clinically relevant copy-number variants in exome sequencing data of patients with dystonia. Parkinsonism and Related Disorders, 2021, 84, 129-134. | 2.2 | 15 |
| 30 | Influence of Disease Severity on Fatigue in Patients with Parkinson's Disease Is Mainly Mediated by Symptoms of Depression. European Neurology, 2013, 70, 201-209. | 1.4 | 13 |
| 31 | WARS2 mutations cause dopa-responsive early-onset parkinsonism and progressive myoclonus ataxia. Parkinsonism and Related Disorders, 2022, 94, 54-61. | 2.2 | 13 |
| 32 | Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes. European Journal of Neurology, 2016, 23, 772-779. | 3.3 | 12 |
| 33 | Prevalence of Prodromal Parkinsonâ€™s Disease as Defined by MDS Research Criteria among Elderly Patients Undergoing Colonoscopy. Journal of Parkinson's Disease, 2017, 7, 481-489. | 2.8 | 12 |
| 34 | Î±â€Synuclein antibody 5G4 identifies manifest and prodromal Parkinson's disease in colonic mucosa. Movement Disorders, 2018, 33, 1366-1368. | 3.9 | 12 |
| 35 | Does the 5â€“2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5â€“2-1-positive patients in 7 countries. BMC Neurology, 2022, 22, 35. | 1.8 | 12 |
| 36 | Ataxia Telangiectasia Gene Mutation in Isolated Segmental Dystonia Without Ataxia and Telangiectasia. Movement Disorders Clinical Practice, 2018, 5, 89-91. | 1.5 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The neurological and neuropsychiatric spectrum of adults with late-treated phenylketonuria. Parkinsonism and Related Disorders, 2021, 89, 167-175. | 2.2 | 11 |
| 38 | Exploding head syndrome â€“ a rare parasomnia or a dissociative episode?. Sleep Medicine, 2014, 15, 728-730. | 1.6 | 10 |
| 39 | Dystonia as a prominent presenting feature in developmental and epileptic encephalopathies: A case series. Parkinsonism and Related Disorders, 2021, 90, 73-78. | 2.2 | 9 |
| 40 | Extensive validation study of the Parkinson's Disease Composite Scale. European Journal of Neurology, 2019, 26, 1281-1288. | 3.3 | 8 |
| 41 | Genetic overlap between dystonia and other neurologic disorders: A study of 1,100 exomes. Parkinsonism and Related Disorders, 2022, 102, 1-6. | 2.2 | 8 |
| 42 | Opsoclonus-myoclonus ataxia syndrome secondary to venlafaxine intoxication. Journal of the Neurological Sciences, 2017, 372, 19-20. | 0.6 | 7 |
| 43 | A Recurrent <scp>VPS16</scp> p.Arg187* Nonsense Variant in Earlyâ€Onset Generalized Dystonia. Movement Disorders, 2021, 36, 1984-1985. | 3.9 | 7 |
| 44 | Scoring Algorithmâ€Based Genomic Testing in Dystonia: A Prospective Validation Study. Movement Disorders, 2021, 36, 1959-1964. | 3.9 | 7 |
| 45 | Variant recurrence confirms the existence of a FBXO31â€related spasticâ€dystonic cerebral palsy syndrome. Annals of Clinical and Translational Neurology, 2021, 8, 951-955. | 3.7 | 6 |
| 46 | Selfâ€rated health mediates the association between functional status and healthâ€related quality of life in <scp>P</scp>arkinson's disease. Journal of Clinical Nursing, 2014, 23, 1970-1977. | 3.0 | 5 |
| 47 | Whole exome sequencing identifies a homozygous POLG2 missense variant in an adult patient presenting with optic atrophy, movement disorders, premature ovarian failure and mitochondrial DNA depletion. European Journal of Medical Genetics, 2020, 63, 103821. | 1.3 | 5 |
| 48 | Predictors of outcome events and 6-year mortality after carotid endarterectomy and carotid stenting in patients with carotid artery stenosis. Neurologia I Neurochirurgia Polska, 2021, 55, 67-73. | 1.2 | 5 |
| 49 | Comparison in detection of prodromal Parkinson's disease patients using original and updated MDS research criteria in two independent cohorts. Parkinsonism and Related Disorders, 2021, 87, 48-55. | 2.2 | 5 |
| 50 | Validation of the Official Slovak Version of the Unified Dyskinesia Rating Scale (UDysRS). Parkinson's Disease, 2015, 2015, 1-7. | 1.1 | 4 |
| 51 | Alzheimerâ€™s Disease-Associated SNP rs708727 in SLC41A1 May Increase Risk for Parkinsonâ€™s Disease: Report from Enlarged Slovak Study. International Journal of Molecular Sciences, 2022, 23, 1604. | 4.1 | 4 |
| 52 | Lack of Accredited Clinical Training in Movement Disorders in Europe, Egypt, and Tunisia. Journal of Parkinson's Disease, 2020, 10, 1833-1843. | 2.8 | 3 |
| 53 | Recessive null-allele variants in MAG associated with spastic ataxia, nystagmus, neuropathy, and dystonia. Parkinsonism and Related Disorders, 2020, 77, 70-75. | 2.2 | 3 |
| 54 | Prevalence of Fabry Disease among Patients with Parkinsonâ€™s Disease. Parkinson's Disease, 2022, 2022, 1-8. | 1.1 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Skin Conditions and Movement Disorders: Hiding in Plain Sight. Movement Disorders Clinical Practice, 2022, 9, 566-583. | 1.5 | 3 |
| 56 | Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. Movement Disorders, 2018, 33, 499-500. | 3.9 | 2 |
| 57 | Neuromodulation Options and Patient Selection for Parkinson's Disease. Neurology India, 2020, 68, 170. | 0.4 | 2 |
| 58 | Effect of Pillbox Organizers with Alarms on Adherence to Pharmacotherapy in Parkinson Disease Patients Taking Three and More Daily Doses of Dopaminergic Medications. Journal of Personalized Medicine, 2022, 12, 179. | 2.5 | 2 |
| 59 | Validation of the Arabic Version of the Movement Disorder Societyâ€Unified Parkinson's Disease Rating Scale. Movement Disorders, 2022, 37, 826-841. | 3.9 | 2 |
| 60 | Atypical presentations of DYT1 dystonia with acute craniocervical onset. Parkinsonism and Related Disorders, 2021, 83, 54-55. | 2.2 | 1 |
| 61 | LRRK2 mutations in Parkinson's disease patients from Central Europe: A case control study. Parkinsonism and Related Disorders, 2021, 83, 110-112. | 2.2 | 1 |
| 62 | Reply: Hoehn and Yahr stage 3 and Postural stability item in the Movement Disorder Societyâ€Unified Parkinson's Disease Rating Scale. Movement Disorders, 2018, 33, 1189-1190. | 3.9 | 0 |
| 63 | Answer to Finsterer about â€œMultisystem presentation of a homozygous POLG2 variantâ€. European Journal of Medical Genetics, 2020, 63, 103900. | 1.3 | 0 |
| 64 | for , , , and in Parkinsonâ€™s. Neuromethods, 2021, , 227-269. | 0.3 | 0 |
| 65 | Impact of the COVID-19 outbreak on neurological consultation in an emergency department. Acta Neurologica Belgica, 2022, , 1. | 1.1 | 0 |
| 66 | Progressive choreodystonia in Xâ€linked <scp>hyperâ€IgM</scp> immunodeficiency: a rare but recurrent presentation. Annals of Clinical and Translational Neurology, 2022, , . | 3.7 | 0 |